On the public citation graph
Characterization of Immune Checkpoint Inhibitor-Associated Arthritis: Insights from the Two Global Pharmacovigilance Databases of FAERS and VigiBase
0 signed · 30 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamaoncol.2020.4564openalex-extracted
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
inferredcites →https://doi.org/10.1002/acr.23177openalex-extracted
Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
inferredcites →https://doi.org/10.1016/j.celrep.2021.109902openalex-extracted
Arthritis flares mediated by tissue-resident memory T cells in the joint
inferredcites →https://doi.org/10.1016/j.semarthrit.2018.02.011openalex-extracted
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
inferredcites →https://doi.org/10.1017/s0033291722002859openalex-extracted
Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database
inferredcites →https://doi.org/10.1038/s41467-020-18742-9openalex-extracted
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
inferredcites →https://doi.org/10.1038/s41467-024-45213-2openalex-extracted
Single-cell insights into immune dysregulation in rheumatoid arthritis flare versus drug-free remission
inferredcites →https://doi.org/10.1038/sdata.2016.26openalex-extracted
A curated and standardized adverse drug event resource to accelerate drug safety research
inferredcites →https://doi.org/10.1056/nejmoa1910231openalex-extracted
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1080/1744666x.2024.2323966openalex-extracted
Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy
inferredcites →https://doi.org/10.1097/bor.0000000000000701openalex-extracted
Treatment of immune checkpoint inhibitor-induced inflammatory arthritis
inferredcites →https://doi.org/10.1097/rhu.0000000000001370openalex-extracted
Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series.
inferredcites →https://doi.org/10.1111/ijcp.13045openalex-extracted
Are obesity and rheumatoid arthritis interrelated?
inferredcites →https://doi.org/10.1136/annrheumdis-2016-209595openalex-extracted
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
inferredcites →https://doi.org/10.1136/annrheumdis-2017-211216openalex-extracted
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
inferredcites →https://doi.org/10.1136/annrheumdis-2019-216109openalex-extracted
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
inferredcites →https://doi.org/10.1136/jitc-2021-003260openalex-extracted
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
inferredcites →https://doi.org/10.1136/rmdopen-2016-000412openalex-extracted
Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity
inferredcites →https://doi.org/10.1136/rmdopen-2018-000714openalex-extracted
Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy
inferredcites →https://doi.org/10.1155/2024/6631033openalex-extracted
Interleukin‐18 Gene Polymorphisms and Rheumatoid Arthritis Susceptibility: An Umbrella Review of Meta‐Analyses
inferredcites →https://doi.org/10.1186/1471-2105-14-7openalex-extracted
GSVA: gene set variation analysis for microarray and RNA-Seq data
inferredcites →https://doi.org/10.1186/1471-2288-12-81openalex-extracted
To test or not to test: Preliminary assessment of normality when comparing two independent samples
inferredcites →https://doi.org/10.3389/fimmu.2023.1197364openalex-extracted
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
inferredcites →https://doi.org/10.3389/fimmu.2023.1260839openalex-extracted
Ferroptosis as an emerging target in rheumatoid arthritis
inferredcites →https://doi.org/10.3389/fimmu.2023.1274060openalex-extracted
Type-I interferon pathway and DNA damage accumulation in peripheral blood of patients with psoriatic arthritis
inferredcites →https://doi.org/10.3389/fimmu.2024.1331959openalex-extracted
Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach
inferredcites →https://doi.org/10.3389/fphar.2023.1199031openalex-extracted
Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
inferredcites →https://doi.org/10.3390/biom11070944openalex-extracted
Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions
inferredcites →https://doi.org/10.3390/jcm13010055openalex-extracted
Tailoring Rheumatoid Arthritis Treatment through a Sex and Gender Lens
inferredcites →https://doi.org/10.4103/jipo.jipo_12_19openalex-extracted
Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting System
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.